Clinuvel Pharmaceuticals Limited Stock Xetra
Stocks
UR9
AU000000CUV3
Pharmaceuticals
OTC Markets Traded| Market Cap | 410M 292M 253M 240M 217M 408M 28.05B 2.86B 1.1B 14.23B 1.1B 1.07B 45.35B | P/E 2027 * |
11.4x | P/E 2028 * | 10.8x |
|---|---|---|---|---|---|
| Enterprise Value | 126M 89.93M 77.93M 73.66M 66.87M 125M 8.63B 879M 340M 4.38B 338M 330M 13.95B | EV / Sales 2027 * |
1.33x | EV / Sales 2028 * | 0.9x |
| Free-Float |
83.79% | Yield 2027 * |
0.67% | Yield 2028 * | 0.8% |
Last Transcript: Clinuvel Pharmaceuticals Limited
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 01/11/2005 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 30/06/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 29/01/2018 |
Susan Smith
BRD | Director/Board Member | - | 23/09/2019 |
| Chairman | - | 01/01/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 292M | |
| +0.06% | -4.09% | +34.70% | -5.93% | 77.35B | |
| +1.54% | +4.50% | -11.91% | -33.33% | 59.58B | |
| +1.29% | +7.38% | +486.23% | +27.08% | 58.14B | |
| -0.21% | -2.96% | -11.54% | +25.36% | 47.62B | |
| -1.81% | +0.73% | +1.08% | +144.77% | 45.34B | |
| -0.07% | +2.51% | +50.34% | -15.22% | 31.92B | |
| +2.47% | -1.00% | +48.69% | +99.44% | 25.29B | |
| +2.55% | +2.28% | 0.00% | +142.16% | 21.08B | |
| -0.05% | -0.86% | +57.38% | +95.99% | 15.64B | |
| Average | +0.37% | -0.13% | +72.77% | +53.37% | 42.42B | |
| Weighted average by Cap. | +0.18% | -0.00% | +87.65% | +35.16% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 94.86M 67.66M 58.64M 55.42M 50.31M 94.3M 6.49B 662M 256M 3.29B 254M 249M 10.49B | 103M 73.49M 63.68M 60.19M 54.64M 102M 7.05B 719M 278M 3.58B 276M 270M 11.4B |
| Net income | 36.02M 25.69M 22.26M 21.04M 19.1M 35.8M 2.46B 251M 97.07M 1.25B 96.5M 94.36M 3.98B | 38.1M 27.18M 23.55M 22.26M 20.21M 37.87M 2.61B 266M 103M 1.32B 102M 99.82M 4.21B |
| Net Debt | -284M -202M -175M -166M -151M -282M -19.43B -1.98B -765M -9.85B -761M -744M -31.41B | -317M -226M -196M -185M -168M -315M -21.71B -2.21B -855M -11.01B -850M -831M -35.1B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
